



Your Lifetime Pharmacy Solution

HEPATITIS C ENROLLMENT FORM

Phone: 813-871-5161 Ext. 34993

Fax: 813-877-2479

PATIENT INFORMATION (COMPLETE THE FOLLOWING OR ATTACH PATIENT DEMOGRAPHIC SHEET)

Patient Name		<input type="checkbox"/> Male <input type="checkbox"/> Female	Allergies	
Date of Birth	SSN#	Patient Weight	Height	Date
Address		City	State	Zip
Phone # (Home)	(Work/Cell)	Email address		

INSURANCE INFORMATION (COMPLETE THE FOLLOWING OR COPY AND ATTACH THE FRONT AND BACK OF INSURANCE AND PRESCRIPTION DRUG CARD)

Primary Insurance		Policyholder
Group #	Policy #	Phone #
Secondary Insurance	Policy#	Phone #

DIAGNOSIS/CLINICAL INFORMATION (PLEASE SEND RECENT CLINICAL NOTES, LABS, & CURRENT MEDICATIONS TO EXPIDITE THE PRIOR AUTHORIZATION)

B18.2 Hepatitis C (Chronic) Other ICD-10 _____ Genotype: _____ HCV/HBV viral load _____ IU/ml
 Date of Last Labs ____/____/____ HIV Co-Infection? Yes No

Is patient: Naïve Partial Responder Non- Responder Relapser Interferon Intolerant Ribavirin Intolerant

NS5A RAVs: Yes No Previous Treatment & Date: _____

Liver Biopsy performed? Yes No **Fibrosure Performed** Yes No **Fibroscan Performed** Yes No _____ KPa

Fibrosis Score _____

Does patient have chronic HCV w/compensated liver disease? Yes No Is patient cirrhotic? Yes No

PRESCRIPTION INFORMATION (COMPLETE DRUG THERAPY INFORMATION OR ATTACH COMPLETED PRESCRIPTION)

Medication	Dose	Frequency	Quantity	Refill
<input type="checkbox"/> EPCLUSA® (sofosbuvir & velpatasvir)	<input type="checkbox"/> 400mg/100 mg tablet	<input type="checkbox"/> orally one time daily for 12 weeks	28 day supply	
<input type="checkbox"/> MAVYRET™ (glecaprevir 100 mg & pibrentasvir 40 mg)	<input type="checkbox"/> 300mg/120 mg 3 tablet regimen	<input type="checkbox"/> orally one time daily w/food for 8 weeks <input type="checkbox"/> orally one time daily w/food for 12 weeks <input type="checkbox"/> orally one time daily w/food for 16 weeks	28 day supply	
<input type="checkbox"/> HARVONI® (ledipasvir & sofosbuvir)	<input type="checkbox"/> 90mg/400 mg tablet	<input type="checkbox"/> orally one time daily for 8 weeks <input type="checkbox"/> orally one time daily for 12 weeks <input type="checkbox"/> orally one time daily for 24 weeks	28 day supply	
<input type="checkbox"/> ZEPATIER® (elbasvir & grazoprevir)	<input type="checkbox"/> 50mg/100 mg tablet	<input type="checkbox"/> orally one time daily for 12 weeks <input type="checkbox"/> orally one time daily for 16 weeks	28 day supply	
<input type="checkbox"/> VOSEVI™ (sofosbuvir 400 mg/velpatasvir 100 mg/voxilaprevir 100 mg)	<input type="checkbox"/> 400mg/100mg/100mg tablet	<input type="checkbox"/> orally one time daily w/food for 12 weeks	28 day supply	
<input type="checkbox"/> Ribavirin 200mg capsules or tablets	Take _____ PO in AM & _____ PO in PM		28 day supply	
<input type="checkbox"/> Other: _____	Dose: _____	Frequency: _____		

DELIVERY INSTRUCTIONS

Provider's Office Patient's Home

1st dose to Provider's Office, refills to patient home Requested Therapy Start Date: ____/____/____

PROVIDER CONTACT INFORMATION & AUTHORIZATION

Provider Name:	Office Contact:	Email:
Phone:	Fax:	Institution:
Address:	City:	
License #	Tax ID:	NPI #

Provider's Signature _____ **Date** _____

*Prescriber Authorization: I authorize this pharmacy and its representatives to act as my authorized agent to secure coverage and initiate the insurance prior authorization process for my patient(s), and to sign any necessary forms on my behalf as my authorized agent, including the receipt of any required prior authorization forms and the receipt and submission of patient lab values and other patient data. In the event that this pharmacy determines that it is unable to fulfill this prescription, I further authorize this pharmacy to forward this information and any related materials related to coverage of the product to another pharmacy of the patient's choice or in the patient's insurer's provider network.
 The information contained in this transmission may contain privileged and confidential information, including patient information protected by federal and state privacy laws. It is intended only for the use of the person(s) named above. If you are not the intended recipient, you are hereby notified that any review, dissemination, distribution, or duplication of this communication is strictly prohibited. If you are not the intended recipient, please contact the sender and destroy all copies of the original document.